Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 10/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5274510 | 0.88 | CACNA1B (0.50) | CACNA1BMEN1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5240648 | 0.87 | CACNA1B (0.48) | CACNA1BMEN1 | |
| SCHEMBL14432339 | 0.82 | CACNA1B (0.55) | CACNA1BMEN1SLC6A4SLC6A3 | |
| SCHEMBL5751875 | 0.82 | HTR1A (0.54) | CACNA1BMEN1 | |
| SCHEMBL2866236 | 0.81 | CACNA1B (0.52) | CACNA1BMEN1CCR1 | |
| Hydrochloric Acid SCHEMBL5754015 | 0.80 | CACNA1B (0.53) | CACNA1BMEN1CCR1 | |
| SCHEMBL5751358 | 0.80 | HTR1A (0.54) | CACNA1BMEN1 | |
| SCHEMBL14431698 | 0.79 | CACNA1B (0.54) | CACNA1BMEN1 | |
| SCHEMBL5752603 | 0.79 | CACNA1B (0.50) | CACNA1BMEN1 | |
| SCHEMBL5237156 | 0.78 | CACNA1B (0.49) | CACNA1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | CACNA1B 2/4885MEN1 3051/4885CCR1 735/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | CACNA1B 1/4885MEN1 2708/4885CCR1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.